Shrooms, Alice, tweezes, mushies, hongos, pizza toppings, magic mushrooms -- everyday lingo for psychedelic mushrooms seems to grow with each generation. Yet leading mycologist Paul Stamets believes it's time for fans of psilocybin mushrooms to leave such childish slang behind."Let's be adults about this. These are no longer 'shrooms.' These are no longer party drugs for young people," Stamets told CNN. "Psilocybin mushrooms are non-addictive, life-changing substances."Small clinical trials that have shown that one or two doses of psylocibin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.Based on this research, the U.S. Food and Drug Administration has described psilocybin as a breakthrough medicine, "which is phenomenal," Stamets said.Psilocybin, which the intestines convert into psilocin, a chemical with psychoactive properties, is also showing promise in combating cluster headaches, anxiety, anorexia, obsessive-compulsive disorder and various forms of substance abuse."The data are strong from depression to PTSD to cluster headaches, which is one of the most painful conditions I'm aware of," said neurologist Richard Isaacson, director of the Alzheimer's Prevention Clinic in the Center for Brain Health at Florida Atlantic University."I'm excited about the future of psychedelics because of the relatively good safety profile and because these agents can now be studied in rigorous double-blinded clinical trials," Isaacson said. "Then we can move from anecdotal reports of 'I tripped on this and felt better' to 'Try this and you will be statistically, significantly better.'"Your brain on mushroomsClassic psychedelics such as psilocybin and LSD enter the brain via the same receptors as serotonin, the body's "feel good" hormone. Serotonin helps control body functions such as sleep, sexual desire and psychological states such as satisfaction, happiness and optimism.People with depression or anxiety often have low levels of serotonin, as do people with post-traumatic stress disorder, cluster headaches, anorexia, smoking addiction and substance abuse. Treatment typically involves selective serotonin reuptake inhibitors, or SSRIs, which boost levels of serotonin available to brain cells. Yet it can take weeks for improvement to occur, experts say, if the drugs even work at all.With psychedelics such as psilocybin and LSD, however, scientists can see changes in brain neuron connectivity in the lab "within 30 minutes," said pharmacologist Brian Roth, a professor of psychiatry and pharmacology at the University of North Carolina at Chapel Hill."One of the most interesting things we've learned about the classic psychedelics is that they have a dramatic effect on the way brain systems synchronize, or move and groove together," said Matthew Johnson, a professor in psychedelics and consciousness at Johns Hopkins Medicine."When someone's on psilocybin, we see an overall increase in connectivity between areas of the brain that don't normally communicate well," Johnson said. "You also see the opposite of that -- local networks in the brain that normally interact with each other quite a bit suddenly communicate less."It creates a "very, very disorganized brain," ultimately breaking down normal boundaries between the auditory, visual, executive and sense-of-self sections of the mind -- thus creating a state of "altered consciousness," said David Nutt, director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.And it's that disorganization that is ultimately therapeutic, according to Nutt: "Depressed people are continually self-critical, and they keep ruminating, going over and over the same negative, anxious or fearful thoughts."Psychedelics disrupt that, which is why people can suddenly see a way out of their depression during the trip," he added. "Critical thoughts are easier to control, and thinking is more flexible. That's why the drug is an effective treatment for depression."The growth of brain cellsThere's more. Researchers say psychedelic drugs actually help neurons in the brain sprout new dendrites, which look like branches on a tree, to increase communication between cells."These drugs can increase neuronal outgrowth, they can increase this branching of neurons, they can increase synapses. That's called neuroplasticity," Nutt said.That's different from neurogenesis, which is the development of brand new brain cells, typically from stem cells in the body. The growth of dendrites helps build and then solidify new circuits in the brain, allowing us to, for example, lay down more positive pathways as we practice gratitude."Now our current thinking is this neuronal outgrowth probably doesn't contribute to the increased connectivity in the brain, but it almost certainly helps people who have insights into their depression while on psilocybin maintain those insights," Nutt said."You shake up the brain, you see things in a more positive way, and then you lay down those positive circuits with the neuroplasticity," he added. "It's a double whammy."Interestingly, SSRIs also increase neuroplasticity, a fact that science has known for some time. But in a 2022 double-blind phase 2 randomized controlled trial comparing psylocibin to escitalopram, a traditional SSRI, Nutt found the latter didn't spark the same magic."The SSRI did not increase brain connectivity, and it actually did not improve well-being as much as psilocybin," Nutt said. "Now for the first time you've got the brain science lining up with what patients say after a trip: 'I feel more connected. I can think more freely. I can escape from negative thoughts, and I don't get trapped in them.' "Taking a psychedelic doesn't work for everyone, Johnson stressed, "but when it works really well it's like, 'Oh my god, it's a cure for PTSD or for depression.' If people really have changed the way their brain is automatically hardwired to respond to triggers for anxiety, depression, smoking -- that's a real thing."How long do results last? In studies where patients were given just one dose of a psychedelic "a couple of people were better eight years later, but for the majority of those with chronic depression it creeps back after four or five months," Nutt said."What we do with those people is unknown," he added. "One possibility is to give another dose of the psychedelic -- we don't know if that would work or not, but it might. Or we could put them on an SSRI as soon as they've got their mood improved and see if that can hold the depression at bay."There are all sorts of ways we could try to address that question," Nutt said, "but we just don't know the answer yet."What about microdosing?Stamets, who over the last 40 years has discovered four new species of psychedelic mushrooms and written seven books on the topic, said he believes microdosing is a solution. That's the practice of taking tiny amounts of a psilocybin mushroom several times a week to maintain brain health and a creative perspective on life.A typical microdose is .01 to .03 grams of dried psilocybin mushrooms, as compared to the 25-milligram pill of psilocybin that creates the full-blown psychedelic experience.Stamets practices microdosing, and has focused on a process called "stacking," in which a microdose of mushrooms is taken with additional substances believed to boost the fungi's benefits. His famous "Stamets Stack" includes niacin, or vitamin B3, and the mycelium, or rootlike structure, of an unusual mushroom called Lion's mane.Surveys of microdosers obtained on his website have shown significantly positive benefits from the practice of taking small doses."These are self-reported citizen scientists projects and we have now around 14,000 people in our app where you register yourself and report your microdose," Stamets told an audience at the 2022 Life Itself conference, a health and wellness event presented in partnership with CNN."I'm going to say something provocative, but I believe it to my core: Psilocybin makes nicer people," Stamets told the audience. "Psilocybin will make us more intelligent, and better citizens."Video below: Psychedelic drugs may improve your cardiovascular healthScientific studies so far have failed to find any benefits from microdosing, leaving many researchers skeptical. "People like being on it, but that doesn't validate the claims of microdosing," Johnson said. "People like being on a little bit of cocaine, too."Experimental psychologist Harriet de Wit, a professor of psychiatry and behavioral science at the University of Chicago, was excited to study microdosing because it solves a key problem of scientific research in the field -- it's hard to blind people to what they are taking if they begin to trip. Microdosing solves that problem because people don't feel an effect from the tiny dose.De Wit specializes in determining whether a drug's impact is due to the drug or what scientists call the "placebo effect," a positive expectation that can cause improvement without the drug.She published a study in early 2022 that mimicked real-world microdosing of LSD, except neither the participants nor researchers knew what was in the pills the subjects took."We measured all kinds of different behavioral and psychological responses, and the only thing we saw is that LSD at very low doses produced some stimulant-like effects at first, which then faded," de Wit said.The placebo effect is powerful, she added, which might explain why the few additional studies done on it have also failed to find any positive results."I suspect microdosing may have an effect on mood, and over time it might build up resilience or improve well-being," Nutt said. "But I don't think it will rapidly fragment depression like macrodosing and going on a trip."A need for cautionObviously, not all hallucinogenic experiences are positive, so nearly every study on psychedelic drugs has included therapists trained to intercede if a trip turns bad and maximize the outcome if the trip is good."This is about allowing someone access into deeper access into their own mental processes, with hopefully greater insight. While others might disagree, it does seem very clear that you need therapy to maximize the benefits," Johnson said.There are also side effects from psychedelics that go beyond a bad trip. LSD, mescaline and DMT, which is the active ingredient in ayahuasca tea, can increase blood pressure, heart rate, and body temperature, according to the National Institute on Drug Abuse. Ayahuasca tea can also induce vomiting. LSD can cause tremors, numbness and weakness, while the use of mescaline can lead to uncoordinated movements. People hunting for psychedelic mushrooms can easily mistake a toxic species for one with psilocybin, "leading to unintentional, fatal poisoning."Another issue: Not everyone is a candidate for psychedelic treatment. It won't work on people currently on SSRIs -- the receptors in their brains are already flooded with serotonin. People diagnosed with bipolar disorder or schizophrenia, or who have a family history of psychosis are always screened out of clinical trials, said Frederick Barrett, associate director of the Center for Psychedelic and Consciousness Research at Johns Hopkins."If you have a vulnerability to psychosis, it could be that exposing you to a psychedelic could unmask that psychosis or could lead to a psychotic event," Barnes said.Then there are the thousands of people with mental health concerns who will never agree to undergo a psychedelic trip. For those people, scientists such as Roth are attempting to find an alternative approach. He and his team recently identified the mechanisms by which psychedelics bond to the brain's serotonin receptors and are using the knowledge to identify new compounds."Our hope is that we can use this information to ultimately make drugs that mimic the benefits of psychedelic drugs without the psychedelic experience," Roth said."What if we could give people who are depressed or suffer from PTSD or anxiety or obsessive-compulsive disorder a medication, and they could wake up the next day and be fine without any side effects? That would be transformative."
Shrooms, Alice, tweezes, mushies, hongos, pizza toppings, magic mushrooms -- everyday lingo for psychedelic mushrooms seems to grow with each generation. Yet leading mycologist Paul Stamets believes it's time for fans of psilocybin mushrooms to leave such childish slang behind.
"Let's be adults about this. These are no longer 'shrooms.' These are no longer party drugs for young people," Stamets told CNN. "Psilocybin mushrooms are non-addictive, life-changing substances."
Small clinical trials that have shown that one or two doses of psylocibin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Based on this research, the U.S. Food and Drug Administration has described psilocybin as a breakthrough medicine, "which is phenomenal," Stamets said.
Psilocybin, which the intestines convert into psilocin, a chemical with psychoactive properties, is also showing promise in combating cluster headaches, anxiety, anorexia, obsessive-compulsive disorder and various forms of substance abuse.
"The data are strong from depression to PTSD to cluster headaches, which is one of the most painful conditions I'm aware of," said neurologist Richard Isaacson, director of the Alzheimer's Prevention Clinic in the Center for Brain Health at Florida Atlantic University.
"I'm excited about the future of psychedelics because of the relatively good safety profile and because these agents can now be studied in rigorous double-blinded clinical trials," Isaacson said. "Then we can move from anecdotal reports of 'I tripped on this and felt better' to 'Try this and you will be statistically, significantly better.'"
Classic psychedelics such as psilocybin and LSD enter the brain via the same receptors as serotonin, the body's "feel good" hormone. Serotonin helps control body functions such as sleep, sexual desire and psychological states such as satisfaction, happiness and optimism.
People with depression or anxiety often have low levels of serotonin, as do people with post-traumatic stress disorder, cluster headaches, anorexia, smoking addiction and substance abuse. Treatment typically involves selective serotonin reuptake inhibitors, or SSRIs, which boost levels of serotonin available to brain cells. Yet it can take weeks for improvement to occur, experts say, if the drugs even work at all.
farmer images
With psychedelics such as psilocybin and LSD, however, scientists can see changes in brain neuron connectivity in the lab "within 30 minutes," said pharmacologist Brian Roth, a professor of psychiatry and pharmacology at the University of North Carolina at Chapel Hill.
"One of the most interesting things we've learned about the classic psychedelics is that they have a dramatic effect on the way brain systems synchronize, or move and groove together," said Matthew Johnson, a professor in psychedelics and consciousness at Johns Hopkins Medicine.
"When someone's on psilocybin, we see an overall increase in connectivity between areas of the brain that don't normally communicate well," Johnson said. "You also see the opposite of that -- local networks in the brain that normally interact with each other quite a bit suddenly communicate less."
It creates a "very, very disorganized brain," ultimately breaking down normal boundaries between the auditory, visual, executive and sense-of-self sections of the mind -- thus creating a state of "altered consciousness," said David Nutt, director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.
And it's that disorganization that is ultimately therapeutic, according to Nutt: "Depressed people are continually self-critical, and they keep ruminating, going over and over the same negative, anxious or fearful thoughts.
"Psychedelics disrupt that, which is why people can suddenly see a way out of their depression during the trip," he added. "Critical thoughts are easier to control, and thinking is more flexible. That's why the drug is an effective treatment for depression."
There's more. Researchers say psychedelic drugs actually help neurons in the brain sprout new dendrites, which look like branches on a tree, to increase communication between cells.
"These drugs can increase neuronal outgrowth, they can increase this branching of neurons, they can increase synapses. That's called neuroplasticity," Nutt said.
That's different from neurogenesis, which is the development of brand new brain cells, typically from stem cells in the body. The growth of dendrites helps build and then solidify new circuits in the brain, allowing us to, for example, lay down more positive pathways as we practice gratitude.
"Now our current thinking is this neuronal outgrowth probably doesn't contribute to the increased connectivity in the brain, but it almost certainly helps people who have insights into their depression while on psilocybin maintain those insights," Nutt said.
"You shake up the brain, you see things in a more positive way, and then you lay down those positive circuits with the neuroplasticity," he added. "It's a double whammy."
Interestingly, SSRIs also increase neuroplasticity, a fact that science has known for some time. But in a 2022 double-blind phase 2 randomized controlled trial comparing psylocibin to escitalopram, a traditional SSRI, Nutt found the latter didn't spark the same magic.
"The SSRI did not increase brain connectivity, and it actually did not improve well-being as much as psilocybin," Nutt said. "Now for the first time you've got the brain science lining up with what patients say after a trip: 'I feel more connected. I can think more freely. I can escape from negative thoughts, and I don't get trapped in them.' "
Taking a psychedelic doesn't work for everyone, Johnson stressed, "but when it works really well it's like, 'Oh my god, it's a cure for PTSD or for depression.' If people really have changed the way their brain is automatically hardwired to respond to triggers for anxiety, depression, smoking -- that's a real thing."
How long do results last? In studies where patients were given just one dose of a psychedelic "a couple of people were better eight years later, but for the majority of those with chronic depression it creeps back after four or five months," Nutt said.
"What we do with those people is unknown," he added. "One possibility is to give another dose of the psychedelic -- we don't know if that would work or not, but it might. Or we could put them on an SSRI as soon as they've got their mood improved and see if that can hold the depression at bay.
"There are all sorts of ways we could try to address that question," Nutt said, "but we just don't know the answer yet."
Stamets, who over the last 40 years has discovered four new species of psychedelic mushrooms and written seven books on the topic, said he believes microdosing is a solution. That's the practice of taking tiny amounts of a psilocybin mushroom several times a week to maintain brain health and a creative perspective on life.
Courtesy Pamela Kryskow
A typical microdose is .01 to .03 grams of dried psilocybin mushrooms, as compared to the 25-milligram pill of psilocybin that creates the full-blown psychedelic experience.
Stamets practices microdosing, and has focused on a process called "stacking," in which a microdose of mushrooms is taken with additional substances believed to boost the fungi's benefits. His famous "Stamets Stack" includes niacin, or vitamin B3, and the mycelium, or rootlike structure, of an unusual mushroom called Lion's mane.
Surveys of microdosers obtained on his website have shown significantly positive benefits from the practice of taking small doses.
"These are self-reported citizen scientists projects and we have now around 14,000 people in our app where you register yourself and report your microdose," Stamets told an audience at the 2022 Life Itself conference, a health and wellness event presented in partnership with CNN.
"I'm going to say something provocative, but I believe it to my core: Psilocybin makes nicer people," Stamets told the audience. "Psilocybin will make us more intelligent, and better citizens."
Video below: Psychedelic drugs may improve your cardiovascular health
Scientific studies so far have failed to find any benefits from microdosing, leaving many researchers skeptical. "People like being on it, but that doesn't validate the claims of microdosing," Johnson said. "People like being on a little bit of cocaine, too."
Experimental psychologist Harriet de Wit, a professor of psychiatry and behavioral science at the University of Chicago, was excited to study microdosing because it solves a key problem of scientific research in the field -- it's hard to blind people to what they are taking if they begin to trip. Microdosing solves that problem because people don't feel an effect from the tiny dose.
De Wit specializes in determining whether a drug's impact is due to the drug or what scientists call the "placebo effect," a positive expectation that can cause improvement without the drug.
She published a study in early 2022 that mimicked real-world microdosing of LSD, except neither the participants nor researchers knew what was in the pills the subjects took.
"We measured all kinds of different behavioral and psychological responses, and the only thing we saw is that LSD at very low doses produced some stimulant-like effects at first, which then faded," de Wit said.
The placebo effect is powerful, she added, which might explain why the few additional studies done on it have also failed to find any positive results.
"I suspect microdosing may have an effect on mood, and over time it might build up resilience or improve well-being," Nutt said. "But I don't think it will rapidly fragment depression like macrodosing and going on a trip."
Obviously, not all hallucinogenic experiences are positive, so nearly every study on psychedelic drugs has included therapists trained to intercede if a trip turns bad and maximize the outcome if the trip is good.
"This is about allowing someone access into deeper access into their own mental processes, with hopefully greater insight. While others might disagree, it does seem very clear that you need therapy to maximize the benefits," Johnson said.
There are also side effects from psychedelics that go beyond a bad trip. LSD, mescaline and DMT, which is the active ingredient in ayahuasca tea, can increase blood pressure, heart rate, and body temperature, according to the National Institute on Drug Abuse. Ayahuasca tea can also induce vomiting. LSD can cause tremors, numbness and weakness, while the use of mescaline can lead to uncoordinated movements. People hunting for psychedelic mushrooms can easily mistake a toxic species for one with psilocybin, "leading to unintentional, fatal poisoning."
Another issue: Not everyone is a candidate for psychedelic treatment. It won't work on people currently on SSRIs -- the receptors in their brains are already flooded with serotonin. People diagnosed with bipolar disorder or schizophrenia, or who have a family history of psychosis are always screened out of clinical trials, said Frederick Barrett, associate director of the Center for Psychedelic and Consciousness Research at Johns Hopkins.
"If you have a vulnerability to psychosis, it could be that exposing you to a psychedelic could unmask that psychosis or could lead to a psychotic event," Barnes said.
Then there are the thousands of people with mental health concerns who will never agree to undergo a psychedelic trip. For those people, scientists such as Roth are attempting to find an alternative approach. He and his team recently identified the mechanisms by which psychedelics bond to the brain's serotonin receptors and are using the knowledge to identify new compounds.
"Our hope is that we can use this information to ultimately make drugs that mimic the benefits of psychedelic drugs without the psychedelic experience," Roth said.
"What if we could give people who are depressed or suffer from PTSD or anxiety or obsessive-compulsive disorder a medication, and they could wake up the next day and be fine without any side effects? That would be transformative."
Continue reading here:
How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety - WYFF4 Greenville
- Cardiology and Cardiac Pharmacology [Last Updated On: April 4th, 2018] [Originally Added On: April 4th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular System ... [Last Updated On: April 8th, 2018] [Originally Added On: April 8th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular ... [Last Updated On: April 11th, 2018] [Originally Added On: April 11th, 2018]
- Cardiology Conferences - Cardiology and Cardiovascular ... [Last Updated On: June 5th, 2018] [Originally Added On: June 5th, 2018]
- Cardiovascular Pharmacology: Open Access - Open Access ... [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- CV Pharmacology | Welcome to Cardiovascular Pharmacology ... [Last Updated On: July 31st, 2018] [Originally Added On: July 31st, 2018]
- Cardiology Conferences | Cardiac pharmacology 2018 ... [Last Updated On: September 13th, 2018] [Originally Added On: September 13th, 2018]
- Cardiology Conference | Cardiac Pharmacology 2019 ... [Last Updated On: November 18th, 2018] [Originally Added On: November 18th, 2018]
- Cardiovascular Pharmacology Online Course | Lecturio [Last Updated On: November 30th, 2018] [Originally Added On: November 30th, 2018]
- Cardiovascular Pharmacology: Open Access [Last Updated On: December 16th, 2018] [Originally Added On: December 16th, 2018]
- Cardiovascular In vivo Models for Drug Discovery [Last Updated On: December 21st, 2018] [Originally Added On: December 21st, 2018]
- UTHSC College of Medicine: Department of Pharmacology [Last Updated On: February 2nd, 2019] [Originally Added On: February 2nd, 2019]
- Department of Pharmacology - School of Medicine - LSU ... [Last Updated On: April 5th, 2019] [Originally Added On: April 5th, 2019]
- Cardiovascular Pharmacology: Open Access - longdom.org [Last Updated On: April 22nd, 2019] [Originally Added On: April 22nd, 2019]
- ASPET | Cardiovascular Pharmacology [Last Updated On: September 14th, 2019] [Originally Added On: September 14th, 2019]
- Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of... [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 - Market Report Gazette [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Pharmacokinetics Market To Increase at Steady Growth Rate - Commerce Gazette [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) - BioSpace [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac fibrosis study identifies key proteins that translate into heart disease - BSA bureau [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23 Annual Scientific Meeting - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Is it risky to continue with blood thinner drugs after a gastrointestinal bleed? - Medical News Bulletin [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Women urged to exercise and eat well due to cholesterol after menopause - Sydney Morning Herald [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Former Executive Director of Preclinical Safety at Novartis, Klaus Peter Hoffmann, MD, PhD, Joins NDA Partners as Expert - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Yale alumna Dr. Nancy Brown named dean of Yale School of Medicine - Yale News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer - Business Wire [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- G-Protein Coupled Receptors (GPCRs) Market Size And Prediction By Leading Manufacturers According To Its Application And Types Till 2022 - Space... [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- Best supplements for blood pressure: The natural remedy proven to lower your reading - Express [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- Advanced Drug Delivery Systems Market Growth Analysis 2019 to Share Key Aspects of the Industry with the details of Influence Factors Forecast to 2024... [Last Updated On: October 28th, 2019] [Originally Added On: October 28th, 2019]
- The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans - Pulmonary Fibrosis News [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT - Yahoo Finance [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- The Montreal Heart Institute celebrates its 500th heart transplant - GlobeNewswire [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Latest Research Report to uncover key Factors of Global Cardiovascular Repair And Reconstruction Devices Market - Market Research Base [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Global Cardiovascular Repair And Reconstruction Devices Market: Development History, Current Analysis and Estimated Forecast to 2025 - Market Research... [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- The cardiac safety services market is projected to reach USD 752 million by 2024 from USD 442 million in 2019, at a CAGR of 11.2% - Yahoo Finance [Last Updated On: December 11th, 2019] [Originally Added On: December 11th, 2019]
- Evaluation of the Effect of Fish Oil Alone and in Combination with a P | DMSO - Dove Medical Press [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Amarin's Multiple Positives And Other News: The Good, Bad, And Ugly Of Biopharma - Seeking Alpha [Last Updated On: January 25th, 2020] [Originally Added On: January 25th, 2020]
- Heres What We Know About CBDs Effects On Varicose Veins - The Fresh Toast [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Hypertension: This Spice Can Help You Control High Blood Pressure Easily And Effectively - Doctor NDTV [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Cannabis Manual: Better Together - Weekly Alibi [Last Updated On: January 30th, 2020] [Originally Added On: January 30th, 2020]
- Pharmacology: Cardiovascular Drugs 1 (30 Items) - Nurseslabs [Last Updated On: March 1st, 2020] [Originally Added On: March 1st, 2020]
- A central master driver of psychosocial stress responses in the rat - Science Magazine [Last Updated On: March 9th, 2020] [Originally Added On: March 9th, 2020]
- The Global Cardiac Safety Services Market is expected to grow from USD 419.45 Million in 2018 to USD 865.23 Million by the end of 2025 at a Compound... [Last Updated On: March 29th, 2020] [Originally Added On: March 29th, 2020]
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment -... [Last Updated On: March 29th, 2020] [Originally Added On: March 29th, 2020]
- Fresh Produce In Short Supply? Prioritize This Veggie In Your Diet - mindbodygreen.com [Last Updated On: April 25th, 2020] [Originally Added On: April 25th, 2020]
- COVID-19: What's RNA research got to do with it? - University of Rochester [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- What Happens When You Add Other Drugs To Your LSD Trip? - VICE [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- Toward a Pharmacology of Resolution - Harvard Magazine [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- GLYCOMIMETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- This Simple Breathing Advice From A Nobel Prize Winner Can Turn The Tables On Stress During The Coronavirus Lockdown - Forbes [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- National Nurses Week 2020: What Experiences Have Shaped Your Nursing Career? - HealthLeaders Media [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- Research Paper Stresses Importance of Repurposing Drugs Against COVID-19 - BioSpace [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- Repurposing existing drugs to treat coronavirus will likely be quicker than a vaccine, scientists claim - CNBC [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- Alzheimer's and Cannabis - Greenway - Greenway [Last Updated On: May 18th, 2020] [Originally Added On: May 18th, 2020]
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day - Business Wire [Last Updated On: June 2nd, 2020] [Originally Added On: June 2nd, 2020]
- Healthy people shouldn't take daily aspirin to prevent heart disease, review finds - WDJT [Last Updated On: June 6th, 2020] [Originally Added On: June 6th, 2020]
- Study reveals how living close to roadways may impact the brain - Drew Reports News [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- Disruptions in circadian rhythms not only cause sleep disorders, but could also put you at risk of these... - Firstpost [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- NeonMind Files Patent Application for Therapeutic Use of DMT - Yahoo Finance [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- Vitamin D What you need to know about the sunshine vitamin - Medical News Bulletin [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- Idorsia announces positive results in the second Phase 3 study of daridorexant - GlobeNewswire [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse - PRNewswire [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- Drug Discovery Outsourcing Market Highly Favorable with new Demand to the Growth Rate by 2027| Thermo Fisher Scientific, Merck KGaA, Albany Molecular... [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Bringing Peer Review To Early COVID-19 Research, More News - Bio-IT World [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Cardiac Safety Services Market Research Report by Type of Service, by Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- UCI study finds women with diabetes and high levels of coronary artery calcium at greater risk of death than men - Newswise [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Globa Advanced Drug Delivery Systems Market 2020 Research, Key Players, Industry Overview, Supply and Consumption Analysis 2024 - Bulletin Line [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Esperion Announces Two Data Presentations of NEXLETOL (bempedoic acid) Tablet at the ESC Congress 2020 - GlobeNewswire [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Women with diabetes and high levels of coronary artery calcium at greater risk of death than men - UCI News [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- 15 Clever Ways to Use Leftover Red Wine - Yahoo Lifestyle [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- UK Study Leads to Better Understanding of Blood Pressure Regulation, Atherosclerosis - UKNow [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Academic always top of the class for pay and conditions - Extra.ie [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- Cardiac Safety Services Market Size Is Rising Tremendously Due To Increasing Need of Healthcare Services Centralization Till 2025 - TC BizNews [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- 5 Benefits of Berberine, Including Why It's a Healthy Gut All-Star - msnNOW [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- Advanced Drug Delivery Systems Market 2020 Report Covers Key Growth Factors, Global Trends, Opportunities by Regions, Industry Size and Share... [Last Updated On: September 23rd, 2020] [Originally Added On: September 23rd, 2020]
- Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small... [Last Updated On: September 23rd, 2020] [Originally Added On: September 23rd, 2020]
- MASSIVE GROWTH OF DRUG DISCOVERY SERVICES MARKET WILL RAISE USD 19.1 BILLION BY 2027, CAGR +13% FROM 2020 TO 2027 WITH TOP KEY PLAYERS LIKE THERMO... [Last Updated On: September 29th, 2020] [Originally Added On: September 29th, 2020]